(Q46525578)

22 December 2017

title

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy (English)

1 reference

22 December 2017

0 references

0 references

1 reference

4

1 reference

22 December 2017

author name string

Finlay A McAlister

series ordinal

1

1 reference

22 December 2017

Dean T Eurich

series ordinal

2

1 reference

22 December 2017

Sumit R Majumdar

series ordinal

3

1 reference

22 December 2017

publication date

19 June 2008

1 reference

22 December 2017

European Journal of Heart Failure

published in

1 reference

22 December 2017

volume

10

1 reference

22 December 2017

issue

7

1 reference

22 December 2017

page(s)

703-708

1 reference

22 December 2017

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Pioglitazone initiation and subsequent hospitalization for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Immortal time bias in pharmaco-epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

A chronic disease score from automated pharmacy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Use of comorbidity scores for control of confounding in studies using administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Increasing glucose levels and BMI predict future heart failure experience from the Reykjavík Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Glycemic control and heart failure among adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Managing the patient with diabetes mellitus and heart failure: issues and considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Cardiovascular effects of sulphonylureas: role of K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2008.05.013

10.1016/J.EJHEART.2008.05.013

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017